Time to stop ovarian cancer screening in BECA1/2 mutation carriers?

International Journal of Cancer

Volumn 124, Issue 4, 2009, Pages 919-923

  Van der Velcie, Nienke M ^a   Mounts, Marian J E ^a   Arts, Henriëtte J G ^a   De Vries, Jacob ^a   Leegte, Beike K ^a   Dijkhuis, Grieteke ^a   Oosterwijk, Jan C ^a   De Bock, Geertruida H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

BRCA2; BRCAI; Hereditary cancer; Ovarian cancer; Screening; Treatment outcome

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER SCREENING; FAMILIAL CANCER; FEMALE; GENE MUTATION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; OVARY CANCER; PELVIMETRY; PREDICTION AND FORECASTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; ADOLESCENT; BIOSYNTHESIS; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OVARY TUMOR; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; CA-125 ANTIGEN; DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 58149461571     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24038     Document Type: Article

References (34)

1. Miki Y, Swensen J, Shattuck-Eiclens D, Futreal PA, Hantaan K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCAI. Science 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C. Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
3. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McA-dams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCAI and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
4. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-24.
5. Chen S. Parmigiani G. Meta-analysis of BRCAI and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
6. Cohen CI, Jennings TS. Screening for ovarian cancer: the role of noninvasive imaging techniques. Am J Obstet Gynecol 1994:170:1088-94.
7. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA. Survival in familial, BRCA1-associated, BRCA2-associated epithelial ovarian cancer. United Kingdom coordinating committee for cancer research (UKCCCR) familial ovarian cancer study group. Cancer Res1999;59:868-71.
8. Shaw PA, McLaughlin JR, Zweemer RP, Narocl SA, Risch H, Yerheijen RH, Ryan A, Menko FH, Kenemans P, Jacobs IJ Histopathologic features of genetically determined ovarian cancer. Tnt J Gynecol Pathol 2002;21:407-11.
9. Werness BA, Ramus SJ, Whittemore AS, Garlinghouse-Jones K, Oak-ley-Girvan I, Dicioccio RA, Tsukada Y, Ponder BA, Piver MS. Histo-pathology of familial ovarian tumors women from families with and without germline BRCAI mutations. Hum Pathol 2000;31:1420-4.
10. Hogg R, Friedlander M. Biology of epithelial ovarian cancer; implications for screening women at high genetic risk. J Clin Oncol2004;22:1315-27.
11. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Mer-rett S, McGuffog L, Steele D, Devilee P, Klijn JG, Meijers-Heijboer H, Radice P. et ai. Pathology of ovarian cancers in BRCAI and BRCA2 carriers. Clin Cancer Res 2004;10:2473-81.
12. Hermsen BB, Olivier RI, Verheijen RH, Van Beurden M, De Hullu JA, Massuger LF, Burger CW, Brekelraans CT, Mourits MJ, De Bock GH, Gaarenstroora KN, Van Boven HH, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers: an observational follow-up study. Br J Cancer 2007;96:1335-42.
13. www.nvog.nl.
14. Sassone AM, Tiraor-Tritsch IE, Artner A, Wetshoff C, Warren WB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78:70-6.
15. Muto MG, Cramer DW, Brown DL, Welch WR, Harlow BL, Xu H, Bracks JP, Tsao SW, Berkowitz RS. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol 1993;51:12-20.
16. Mann WJ, Patsner B, Coher H, Loeseh M. Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma. J Natl Cancer Inst 1998;80:208-13.
17. Jacobs I, Bast RC, jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-5
18. Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 2006;94:814-19.
19. Gaarenstroom KN, Van der Hiel B, Tollenaar RAEM, Vink GR, Jan-sen FW, Van Asperen CI, Renter GG. Efficacy of screening at high risk of hereditary ovarian cancer: results of an 11-year cohort study, bit J Gynecol Cancer 2006; 16:54-9.
20. Olivier RI, Lubsen-Brandsma MAC, Verhoef S, Van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006;100:20-6.
21. Vasen HFA, Tesfay E, Boonstra H, Mourits MJ, Rutgers E, Verheyen R, Oosterwijk J, Beex L. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 2005 ;41:549-54.
22. Meeuwissen PAM, Seynaeve C, Brekelraans CTM, Meijers-Heijboer HJ, Klijn JGM, Burger CW. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 2005;97:476-82.
23. Stirling D, Evans DG, Pichert G, Shenton A, Kirk EN, Rimmer S, Steel CM, Lawson S, Busby-Earle RM, Walker J, Lalloo Ft, Eccles DM, et al. Screening for familial ovarian cancer failure of current protocols to detect ovarian cancer at an early stage according to the international federation of gynecology and obstetrics system. J Clin Oncol 2005;23:5588-96.
24. Laframboise S, Nedeleu R, Murphy J, Cole DEC, Rosen B. Use of CA-125 and ultrasound in high-risk women. Int J Gynecol Cancer 2002;12:86-91.
25. Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002;20:1260-8.
26. Dørum A, Heimdal K, Løvslett K, Kristensen G, Hansen LJ, Sandvei R, Schiefioe A, Hagen B, Himmelmann A, Jerve F, Shetelig K, Fjaer-estad I, et ai. Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 1999;78:906-11.
27. Bosse K, Rhiem K, Wappenschmidt B, Hellmich M, Madeja M, Ort-mann M, Mailmann P, Schmutzier R. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol Oncol 2006;103:1077-82.
28. Jacobs IJ, Skates SJ, Mac Donald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.
29. Bast RC, Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 2007;174:91-100.
30. Zhang Z, Yu Y, Xu F, Berchuck A, Van Haaften-Day C, Havrilesky LJ, De Bruijn HW, Van der Zee AG, Woolas RP, Jacobs IL Skates S, Chan DW, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 2007; 107:526-31.
31. Liu C, Shea N, Rucker S, Harvey L, Russo P, Saul R, Lopez MF, Mikulskis A, Kuzdzal S, Golenko E, Fishman D, Vonderheid E, et ai. Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. Proteomics 2007;7:4045-52.
32. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiei M, et al. Risk-reducing salpingo-oophorectomy in women with a BRCAI or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
33. Rebbeck TR, Lynch HT,Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade 01, Weber BL. Prevention and observation of surgical end points study group. Prophylactic oophorectomy in carriers of BRCAI or BRCA2 mutations. N Engl J Med 2002;346:1616-22
34. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CTM, Seynaeve C, Tilanus-Linthorst MM, Wagner A, Dukel L, Devilee P, van den Ouweland AM, van Geel AN, Klijn JG. Presymptomatic DNA testing and prophylactic surgery in families with a BRCAI or BRCA 2 mutation. Lancet 2000;335:2015-20.